Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: CIN Clear all
Completed Phase 2 Interventional

Eflornithine To Prevent Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia

NCT00006079
View directory record Official record
Conditions
Cervical Cancer, Precancerous Condition
Interventions
Eflornithine, Placebo
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Jul 22, 2026, 11:10 AM EDT
Recruiting No phase listed Observational

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

NCT05051722
View directory record Official record
Conditions
Endometrial Cancer, Cervical Cancer, Atypical Endometrial Hyperplasia, Cervical Dysplasia, Adnexal Mass, Ovarian Cancer
Interventions
Vaginal Fluid Collection, Blood Collection
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
3,110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
24
States / cities
Phoenix, Arizona • Jacksonville, Florida • Miami, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Jul 22, 2026, 11:10 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Oral Diindolylmethane (DIM) for the Treatment of Cervical Dysplasia

NCT00212381
View directory record Official record
Conditions
Cervical Dysplasia
Interventions
di indolylmethane (DIM), Red rice bran
Drug · Dietary Supplement
Lead sponsor
New York Presbyterian Hospital
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Jul 22, 2026, 11:10 AM EDT
Not listed Not applicable Interventional

Multispectral Digital Colposcope With Probe for Detection of Cervical Intraepithelial Neoplasia

NCT02406352
View directory record Official record
Conditions
Carcinoma in Situ of Uterine Cervix, Cervical Intraepithelial Neoplasias, High Grade Cervical Intraepithelial Neoplasia
Interventions
Multispectral Digital Colposcope with probe
Device
Lead sponsor
Brookdale University Hospital Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Jul 22, 2026, 11:10 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

TA-CIN Vaccine With Anti-PD-1 Therapy in Recurrent HPV16-associated Cancers

NCT05132803
View directory record Official record
Conditions
Recurrent Human Papillomavirus Type 16 Associated Cancer
Interventions
HPV 16 TA-CIN
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
19 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Birmingham, Alabama • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Jul 22, 2026, 11:10 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Evaluating Materials to Educate Patients About Cervical Dysplasia

NCT00454766
View directory record Official record
Conditions
Education, Cervical Dysplasia
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Jul 22, 2026, 11:10 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Colposcopy Education Using Operant Learning

NCT04340011
View directory record Official record
Conditions
Educational Problems, Cervix, Dysplasia
Interventions
Colposcopy
Other
Lead sponsor
University of Virginia
Other
Eligibility
21 Years and older · Female only
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Jul 22, 2026, 11:10 AM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

C-3002: Enhancing Cervical Cancer Screening Access and Follow-up Care at 'CASCADE' Clinical Sites in the United States

NCT07520188
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV), Cervical Cancer, Cervical Precancer
Interventions
Qualitative interviews, Focus groups
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
25 Years to 49 Years
Enrollment
3,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 22, 2026, 11:10 AM EDT
Completed Phase 2 Interventional

SGN-00101 Immunotherapy in Treating Patients With Grade III Cervical Intraepithelial Neoplasia

NCT00075569
View directory record Official record
Conditions
Cervical Cancer, Precancerous Condition
Interventions
HspE7
Biological
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2018 · Synced Jul 22, 2026, 11:10 AM EDT
Completed Phase 1 Interventional Results available

Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3)

NCT02354534
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia Grade 2/3, High-risk HPV (Any Strain)
Interventions
Artesunate Suppositories
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Baltimore, Maryland • Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Jul 22, 2026, 11:10 AM EDT
Completed Phase 2 Interventional Results available

Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia

NCT00081263
View directory record Official record
Conditions
Cervical Carcinoma, Cervical Intraepithelial Neoplasia Grade 2/3, Stage 0 Cervical Cancer
Interventions
Celecoxib, Laboratory Biomarker Analysis, Placebo
Drug · Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
43
States / cities
Tucson, Arizona • Little Rock, Arkansas • Lewes, Delaware + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Jul 22, 2026, 11:10 AM EDT
Completed Phase 2 Interventional Results available

Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection

NCT00513526
View directory record Official record
Conditions
Infection, Precancerous Condition
Interventions
Gardasil
Biological
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older · Male only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Jul 22, 2026, 11:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Intervention to Improve Follow-up of Abnormal Pap Test

NCT00575510
View directory record Official record
Conditions
Cervical Cancer
Interventions
Intervention, Active control
Behavioral
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
341 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Jul 22, 2026, 11:10 AM EDT
Completed Phase 1Phase 2 Interventional Results available

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

NCT02858310
View directory record Official record
Conditions
Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ, Vulvar Neoplasms, Vulvar Diseases
Interventions
E7 TCR cells, Aldesleukin, Fludarabine, Cyclophosphamide, EKG, Biopsy, Chest CT and MRI or PET, PFT, Granisetron, Ondansetron, Droperidol, Prochlorperazine, Diphenoxylate HCL, Atropine sulfate, Codeine sulfate, Loperamide, Indomethacin, Acetaminophen, Diphenhydramine HCL, Hydroxyzine HCL, Meperidine
Biological · Drug · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
Bethesda, Maryland • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Jul 22, 2026, 11:10 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effect of a Childcare Resource on Cervical Cancer Prevention

NCT06086054
View directory record Official record
Conditions
Cervical Dysplasia
Interventions
Navigation and EMR referral to childcare facility
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Jul 22, 2026, 11:10 AM EDT
Completed Early Phase 1 Interventional Results available

Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia

NCT03196180
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia Grade 2/3, Cervical Squamous Cell Carcinoma In Situ, Cervical Squamous Intraepithelial Neoplasia 2, High Grade Cervical Intraepithelial Neoplasia
Interventions
Imiquimod, Topical Fluorouracil
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Jul 22, 2026, 11:10 AM EDT
Recruiting Phase 1 Interventional

Study of Treatment for HPV16+ ASC-US or LSIL

NCT03913117
View directory record Official record
Conditions
ASC-US, LSIL
Interventions
pNGVL4aCRTE6E7L2, TA-CIN
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Birmingham, Alabama • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jul 22, 2026, 11:10 AM EDT
Enrolling by invitation Not applicable Interventional

The Use of the LuViva Advanced Cervical Scan to Identify Women at High-Risk for Cervical Neoplasia

NCT04915495
View directory record Official record
Conditions
Cervical Dysplasia
Interventions
LuViva Advanced Cervical Scan
Diagnostic Test
Lead sponsor
Guided Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Birmingham, Alabama • Atlanta, Georgia • Bay City, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Jul 22, 2026, 11:10 AM EDT
Completed Early Phase 1 Interventional

Use of High-Resolution Microendoscopy (HRME) in Patients With Cervical Dysplasia

NCT02420665
View directory record Official record
Conditions
Cervical Cancer
Interventions
Proflavine, HRME Imaging, Phone Call, Colposcopy, Acetic Acid
Drug · Device · Behavioral + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Jul 22, 2026, 11:10 AM EDT
Terminated Phase 2 Interventional

An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+

NCT01116245
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia
Interventions
ADXS11-001 (Lm-LLO-E7), Placebo Control
Biological · Drug
Lead sponsor
Advaxis, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
15
States / cities
Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Jul 22, 2026, 11:10 AM EDT
Completed Not applicable Interventional

Protein Expression as a Potential Diagnostic Biomarker of Cervical Dysplasia and/or Cancer

NCT00003384
View directory record Official record
Conditions
Precancerous Condition, Stage 0 Cervical Cancer
Interventions
Cervical Papanicolaou Test, Conization, Laboratory Biomarker Analysis
Other · Procedure
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
684 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Jul 22, 2026, 11:10 AM EDT
Withdrawn Phase 2 Interventional

A Phase II Single-arm Intervention Trial of Nelfinavir in Patients With Grade 2/3 or 3 Cervical Intraepithelial Neoplasia

NCT01925378
View directory record Official record
Conditions
Cervical Dysplasia
Interventions
Nelfinavir
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 11, 2020 · Synced Jul 22, 2026, 11:10 AM EDT
Terminated Phase 1 Interventional

Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL

NCT02689726
View directory record Official record
Conditions
HPV 16- and/or HPV 18-Infected Women With Normal Cytology, ASCUS, or LSIL
Interventions
GTL001+, Aldara
Drug
Lead sponsor
Genticel
Industry
Eligibility
25 Years to 65 Years · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Louisville, Kentucky • Raleigh, North Carolina • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Jul 22, 2026, 11:10 AM EDT
Recruiting Phase 2 Interventional

PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia

NCT07454915
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia Grade 2/3, Human Papilloma Virus Infection Type 16
Interventions
PVX4 Combination Product, Placebo Control
Combination Product · Other
Lead sponsor
PapiVax Biotech, Inc.
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 22, 2026, 11:10 AM EDT